The ability to accurately diagnose liver cancer progression is critical for selecting the appropriate treatment option. Further, various companies and organizations have taken enormous initiatives to develop and implement innovative solutions for the early identification of this disease in response to the rising demand. For instance, in March 2020, Roche Holding AG's Elecsys GALAD score received the US Food and Drug Administration's breakthrough device status for the early detection of an advanced form of liver cancer. The Swiss drugmaker's calculator combines factors including age, gender, and biomarker results to detect early-stage hepatocellular carcinoma, which is the most common form of liver cancer. Further, Elecsys GALAD score is designed to support clinicians by providing them with a timely and accurate diagnosis of hepatocellular carcinoma.
The research and development (R&D) expenditure in 2021 was US$ 14.65 billion, and in 2020, it was US$ 13.17 billion. The research and development (R&D) expenditure grew by 14% on a core basis in F. Hoffmann-La Roche Ltd., mostly driven by late-stage investments in oncology, ophthalmology, and personalized healthcare. In 2021, the R&D investment in the diagnostic division was US$ 1,878.92 million. Similarly, In November 2019, EXACT Sciences Corporation received the Food and Drug Administration's (FDA) breakthrough designation for its blood-based test for early detection of liver cancer.
Additionally, in June 2020, National Institutes of Health (NIH) scientists developed blood tests to help improve liver cancer screening, led by researchers at the National Cancer Institute (NCI). In addition, in June 2019, CancerSEEK, a liquid biopsy test, was designed by researchers at Johns Hopkins University. The test was designed to diagnose multiple cancers, including stomach, liver, ovarian, and esophageal, at an early stage, facilitating early treatment. Therefore, the increasing R&D investments and development of diagnostic tests for the detection of liver cancer are driving the liver cancer diagnostics market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America Liver cancer diagnostics market at a substantial CAGR during the forecast period.
North America Liver Cancer Diagnostics Market Segmentation
The North America liver cancer diagnostics market is analyzed on the basis of type, end user, and country. Based on type, the market is segmented into laboratory tests, imaging, endoscopy, biopsy, and others. In 2021, the laboratory tests segment held the largest share of the market, and the imaging segment is expected to register a higher CAGR during the forecast period.
Based on laboratory tests, the market is segmented into blood tests and biomarkers. In 2021, the blood tests segment held a larger market share, and the same segment is expected to register the highest CAGR in the market during the forecast period.
Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. In 2021, the hospitals and diagnostic laboratories segment held the largest share of the market, and the same segment is expected to register a higher CAGR during the forecast period.
Based on country, the North America liver cancer diagnostics market is segmented into the US, Canada, and Mexico. In 2021, the US held the largest market share, and it is also expected to grow at the fastest CAGR during the forecast period.
Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; Perspectum; and Helio, Inc. are the leading companies in the North America liver cancer diagnostics market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 3,843.93 Million |
| Market Size by 2028 | US$ 6,666.24 Million |
| CAGR (2021 - 2028) | 8.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
The North America Liver Cancer Diagnostics Market is valued at US$ 3,843.93 Million in 2021, it is projected to reach US$ 6,666.24 Million by 2028.
As per our report North America Liver Cancer Diagnostics Market, the market size is valued at US$ 3,843.93 Million in 2021, projecting it to reach US$ 6,666.24 Million by 2028. This translates to a CAGR of approximately 8.2% during the forecast period.
The North America Liver Cancer Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Liver Cancer Diagnostics Market report:
The North America Liver Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Liver Cancer Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Liver Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For North America Liver Cancer Diagnostics Market
